Search the Newsreel

GRAL Investor Alert: HBSS Probes GRAIL, Inc. (GRAL) Following Securities Class Action Over Failed NHS-Galleri Trial

Hagens Berman is investigating GRAIL, Inc. (GRAL) following a class action lawsuit alleging the company misled investors about the design and efficacy of its NHS-Galleri cancer screening trial. The lawsuit claims GRAIL concealed inadequate trial design and withheld critical data, leading to a significant …

GRAL DEADLINE: SueWallSt Reminds Grail, Inc. Investors of Upcoming Securities Class Action Deadline

SueWallSt is reminding investors of Grail, Inc. (NASDAQ: GRAL) about an upcoming securities class action deadline of August 4, 2026. The lawsuit alleges that Grail's leadership withheld detailed results from the NHS-Galleri trial, leading to a 50.55% stock plunge after the trial failed to …

GRAIL, INC. SECURITIES FRAUD NOTICE: Berger Montague Informs GRAIL, Inc. (GRAL) Investors of a Securities Fraud Lawsuit

Berger Montague PC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) on behalf of investors who purchased shares between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL concealed material inadequacies in the NHS-Galleri trial design, leading to …

GRAIL, INC. (GRAL) SHAREHOLDER ALERT Bernstein Liebhard LLP

Bernstein Liebhard LLP has issued a shareholder alert reminding investors of GRAIL, Inc. (NASDAQ: GRAL) about an upcoming August 4, 2026 deadline for a securities fraud class action lawsuit. The lawsuit alleges that GRAIL made false and misleading statements between May 13, 2025, and …

Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri® Multi-Cancer Early Detection Blood Test to Employer Plans

Priority Health, a leading Michigan health plan, has partnered with GRAIL to offer the Galleri multi-cancer early detection blood test to its self-insured employer groups, making it the first in Michigan to do so. This expansion follows Priority Health's earlier integration of Galleri into …

GRAL STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) and its officers. The lawsuit alleges that GRAIL made materially false and misleading statements regarding the likelihood of achieving the primary endpoint in its NHS-Galleri trial between May …

GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Levi & Korsinsky, LLP has announced a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL) for alleged misrepresentations concerning its NHS-Galleri trial. The lawsuit claims that the trial's three-year design was insufficient to achieve its primary endpoint of reducing late-stage cancers, leading to …

$GRAL Investor Loss Alert: GRAIL, Inc. Investors may have been Misled after Channel Stuffing Claims Lead to 50% Stock Drop – Contact BFA Law if You Lost Money

A class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) and its executives for securities fraud after its stock dropped 50%. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, which failed to meet its primary endpoint of reducing late-stage …

EPIGRAL Forecast — Price Target — Prediction for 2027

Integral Diagnostics to Release 178,146 Escrowed Shares on 1 July 2026

Epigral Limited to meet Bellwether Capital on June 16

Integral Diagnostics Upgraded: Risk/Reward Improves, But Not Enough

Can Integral Diagnostics (ASX:IDX) Benefit From Australia’s Growing Healthcare Demand?

Integral Diagnostics And 2 Other ASX Stocks That May Be Trading Below Estimated Value

Epigral Limited's (NSE:EPIGRAL) Sole Analyst Just Made A Substantial Upgrade To Their Forecasts

Epigral Q4 FY26 Conference Call Transcript: Record Revenue of ₹736 Crores, EBITDA Surges 64%

Epigral Consolidated March 2026 Net Sales at Rs 736.16 crore, up 17.29% Y-o-Y

Epigral shares climb 15% on record Q4 revenue; profit under pressure

Epigral Reports Q4FY26 Revenue ₹736cr, Conference Call Recording Available

Epigral consolidated net profit declines 6.84% in the March 2026 quarter

Integral Diagnostics Ltd (ASX:IDX): Medical Imaging Leader Succumbs to Major Structural Breakdown

Epigral - 13 stocks fall up to 45% in 3 months on FII stake cuts, weak earnings

Health Check: Integral says ‘we’re stronger together’ after bumper merger result

One Healthcare Stock with Decent Growth Potential - Integral Diagnostics Limited

Insiders are the top stockholders in Epigral Limited (NSE:EPIGRAL), and the recent 13% drop might have disappointed them

Epigral Limited Schedules Conference Call for Q3FY26 Results Discussion on January 30, 2026

Can Integral Diagnostics Limited's (ASX:IDX) Weak Financials Pull The Plug On The Stock's Current Momentum On Its Share Price?

Epigral Limited Just Missed Earnings - But Analysts Have Updated Their Models

Epigral Anticipates Stronger Performance in H2 FY26 Despite Q2 Revenue Dip

If EPS Growth Is Important To You, Epigral (NSE:EPIGRAL) Presents An Opportunity

Epigral Share Price Plunges 7.29% as Q2 Profit Drops 36% YoY to ₹51 Cr

Q2 results impact: Graphite India, Epigral shares decline up to 7% on weak earnings, Krsnaa Diagnostics...

Integral Diagnostics Shares (ASX:IDX) Move Positive YTD on Earnings

IDX ASX: Integral Diagnostics dealmaking creates $1b diagnostics giant

Resultados financieros de Logista Integral, S.A. – BME:LOG